Kite Pharma, Inc. Insider Trading for November 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for November 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 15,000 | 20,250 | 345,394 | |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 86.90 | 2,600 | 225,940 | 75,507 | 78.1 K to 75.5 K (-3.33 %) |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 86.35 | 12,400 | 1,070,740 | 78,107 | 90.5 K to 78.1 K (-13.70 %) |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 15,000 | 20,250 | 90,507 | 75.5 K to 90.5 K (+19.87 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 33,878 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 102,125 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 79.78 | 445 | 35,502 | 2,198 | 2.6 K to 2.2 K (-16.84 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 78.71 | 2,237 | 176,074 | 2,643 | 4.9 K to 2.6 K (-45.84 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 78.02 | 2,463 | 192,163 | 4,880 | 7.3 K to 4.9 K (-33.54 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 76.53 | 1,000 | 76,530 | 7,343 | 8.3 K to 7.3 K (-11.99 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 8,343 | 7.7 K to 8.3 K (+8.38 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 7,698 | 2.2 K to 7.7 K (+250.23 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 112,000 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 80.20 | 90 | 7,218 | 6,342 | 6.4 K to 6.3 K (-1.40 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 79.25 | 741 | 58,724 | 6,432 | 7.2 K to 6.4 K (-10.33 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 78.55 | 4,598 | 361,173 | 7,173 | 11.8 K to 7.2 K (-39.06 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 77.65 | 2,159 | 167,646 | 11,771 | 13.9 K to 11.8 K (-15.50 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 76.43 | 1,412 | 107,919 | 13,930 | 15.3 K to 13.9 K (-9.20 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 15,342 | 6.3 K to 15.3 K (+141.91 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 133,031 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 80.27 | 172 | 13,806 | 2,941 | 3.1 K to 2.9 K (-5.53 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 79.27 | 944 | 74,831 | 3,113 | 4.1 K to 3.1 K (-23.27 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 78.49 | 5,236 | 410,974 | 4,057 | 9.3 K to 4.1 K (-56.34 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 77.62 | 1,791 | 139,017 | 9,293 | 11.1 K to 9.3 K (-16.16 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 76.46 | 1,424 | 108,879 | 11,084 | 12.5 K to 11.1 K (-11.38 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 12,508 | 2.9 K to 12.5 K (+325.30 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 5,000 | 6,750 | 360,394 | |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 80.00 | 5,000 | 400,000 | 75,507 | 80.5 K to 75.5 K (-6.21 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 5,000 | 6,750 | 80,507 | 75.5 K to 80.5 K (+6.62 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 30,800 | 212,212 | 223,000 | |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 80.02 | 30,800 | 2,464,616 | 6,904 | 37.7 K to 6.9 K (-81.69 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 30,800 | 212,212 | 37,704 | 6.9 K to 37.7 K (+446.12 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 87,000 | |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 72.41 | 110 | 7,965 | 1,888 | 2 K to 1.9 K (-5.51 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 71.64 | 4,899 | 350,964 | 1,998 | 6.9 K to 2 K (-71.03 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 70.87 | 2,876 | 203,822 | 6,897 | 9.8 K to 6.9 K (-29.43 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 69.81 | 525 | 36,650 | 9,773 | 10.3 K to 9.8 K (-5.10 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 68.22 | 590 | 40,250 | 10,298 | 10.9 K to 10.3 K (-5.42 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,888 | 1.9 K to 10.9 K (+476.69 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 253,800 | |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 71.70 | 3,923 | 281,279 | 6,904 | 10.8 K to 6.9 K (-36.23 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 70.96 | 2,800 | 198,688 | 10,827 | 13.6 K to 10.8 K (-20.55 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 69.52 | 500 | 34,760 | 13,627 | 14.1 K to 13.6 K (-3.54 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 68.27 | 477 | 32,565 | 14,127 | 14.6 K to 14.1 K (-3.27 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 14,604 | 6.9 K to 14.6 K (+111.53 %) |